Ann: PARADIGM SUBMITS RESPONSES TO US FDA QUESTIONS, page-13

We weren't made aware of the non-clinical studies that were initially carried out as part of the IND application from where these questions arose. As was the case with the rest of the 30 000 page document. Yes these questions were deemed low level by PAR, but public disclosure to the non-scientific may in fact raise more questions than answers. PAR is obviously satisfied with what they have submitted as it would not make sense to do otherwise. My only concern/disappointment is that BY disclosed the information.